Inovio Net Income from 2010 to 2024

INO Stock  USD 4.19  0.18  4.49%   
Inovio Pharmaceuticals Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to grow to about -128.4 M this year. During the period from 2010 to 2024, Inovio Pharmaceuticals Net Loss quarterly data regression pattern had range of 298.8 M and standard deviation of  94,690,136. View All Fundamentals
 
Net Loss  
First Reported
1998-12-31
Previous Quarter
-32.2 M
Current Value
-25.2 B
Quarterly Volatility
2.5 B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Inovio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inovio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 1.2 M or Total Revenue of 790.4 K, as well as many indicators such as Price To Sales Ratio of 155, Dividend Yield of 1.0E-4 or PTB Ratio of 1.1. Inovio financial statements analysis is a perfect complement when working with Inovio Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

Latest Inovio Pharmaceuticals' Net Income Growth Pattern

Below is the plot of the Net Income of Inovio Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Inovio Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Inovio Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Inovio Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inovio Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (135.12 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Inovio Net Income Regression Statistics

Arithmetic Mean(108,262,657)
Coefficient Of Variation(87.46)
Mean Deviation72,345,374
Median(88,205,772)
Standard Deviation94,690,136
Sample Variance8966.2T
Range298.8M
R-Value(0.78)
Mean Square Error3813T
R-Squared0.61
Significance0.0006
Slope(16,470,605)
Total Sum of Squares125527.1T

Inovio Net Income History

2024-128.4 M
2023-135.1 M
2022-287.7 M
2021-305.4 M
2020-215.1 M
2019-120.6 M
2018-97 M

Other Fundumenentals of Inovio Pharmaceuticals

Inovio Pharmaceuticals Net Income component correlations

About Inovio Pharmaceuticals Financial Statements

Inovio Pharmaceuticals investors utilize fundamental indicators, such as Net Income, to predict how Inovio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-135.1 M-128.4 M
Net Loss-164.6 M-172.8 M
Net Loss-251.8 M-239.2 M
Net Loss(6.09)(6.40)
Net Income Per E B T 1.19  1.13 
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:
Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.43)
Revenue Per Share
0.025
Quarterly Revenue Growth
(0.55)
Return On Assets
(0.40)
Return On Equity
(0.91)
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.